PATH250103C17500
- 0.02
- 0.000.00%
UiPath Newsroom
TD Cowen Maintains UiPath(PATH.US) With Hold Rating, Maintains Target Price $16
UiPath Hold Rating: Awaiting Clearer Evidence of Successful Reorganization and Growth Stabilization
UiPath Analyst Ratings
Needham Maintains UiPath(PATH.US) With Hold Rating
UiPath Is Maintained at Equal-Weight by Barclays
UiPath Analyst Ratings
Barclays Maintains UiPath(PATH.US) With Hold Rating, Cuts Target Price to $15
Barclays Sticks to Their Hold Rating for UiPath (PATH)
Needham Maintains UiPath(PATH.US) With Hold Rating
UiPath Maintains Hold Rating Amid Mixed Demand Signals and Regional Disparities
UiPath Analyst Ratings
UiPath Initiated at Sell by UBS
UiPath Analyst Ratings
UBS Initiates UiPath(PATH.US) With Sell Rating, Announces Target Price $14
A Quick Look at Today's Ratings for UiPath(PATH.US), With a Forecast Between $15 to $18
UiPath Price Target Raised to $16.00/Share From $15.00 by Barclays
UiPath Price Target Raised to $16.00/Share From $15.00 by Morgan Stanley
BMO Capital Maintains Market Perform on UiPath, Raises Price Target to $16
UiPath Price Target Maintained With a $16.00/Share by RBC Capital
UiPath Is Maintained at Overweight by JP Morgan